Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Idexx Laboratories Inc

NASDAQ: IDXX · Life Sciences · 6 alerts · CIK 874716

Share price
$700.65Close, Nov 16
Market cap
$55.2B
Shares outstanding
78.79MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Idexx Laboratories Inc filings on SEC EDGAR ↗

4:29 PM ET 10-Q
Financial Results

Idexx Laboratories Q3 2026 Results: Net Income $317M, Up 15.5% YoY

IDEXX Laboratories reported total revenue of $1.21 billion for the quarter ended September 30, 2026, representing growth over the $1.11 billion reported in the prior year. Net income for the nine months ended September 30, 2026, increased to $934 million, up from $811 million in the same period of 2025, driven by strong performance in both product and service revenue.

Key figure
Net income $317M · +15.5% YoY
6:31 AM ET 8-K
Financial Results

Idexx Laboratories Financial Results

IDEXX Laboratories reported third quarter 2026 revenue of $1.21 billion, up 10% year-over-year, driven by strong growth in its Companion Animal Group. The company delivered EPS of $4.01 and raised its full-year 2026 revenue and EPS guidance based on strong recurring diagnostics performance.

Term
Q3 2026

“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy. Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently.”

Mike Erickson, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.